Since E-cadherin expression loss in cancer cells is strongly connected with tumor progression and a more aggressive phenotype of cells, as well as their worse response to chemical drugs, it opens up an opportunity to consider this protein as a marker of various clinicopathological parameters of ovarian cancer. Here, CDH1 is linked to neoplasm.